Don't Buy INSYS Therapeutics (INSY) In 2018
January 10, 2018 at 09:32 AM EST
From a fundamental valuation point of view, Insys looks to be very overbought. The company is currently not profitable with an earnings per share of -$2.55, while the industry average is +$2.82.
